Search

Your search keyword '"Brehler, Randolf"' showing total 208 results
Start Over Author "Brehler, Randolf" Language english
208 results on '"Brehler, Randolf"'

7. Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy

Author

Pohl, Wolfgang, Doberer, Daniel, Martinot, Jean Benoit, Deschampheleire, Maud, Himpe, Ulrike, Chapman, Kenneth, Cheema, Amarjit, Dorscheid, Delbert, Ramsey, Clare, Rolf, Jeffrey, Walker, Brandie, Olivenstein, Ronald, Poirier, Claude, Larivee, Pierre, Bjerrum, Anne Sofie, Titlestad, Ingrid, Hilberg, Ole, Kilpeläinen, Maritta, Bonniaud, Philippe, Taillé, Camille, Tiotiu, Iuliana-Angelica, Girodet, Pierre-Olivier, Blanc, François-Xavier, Pradelli, Johana, Didier, Alain, Nocent Ejnaini, Cecilia, Deslee, Gaetan, Pison, Christophe, Douadi, Youcef, Mahay, Guillaume, Devouassoux, Gilles, Melloni, Boris, Roux, Pauline-Marie, Bourdin, Arnaud, Fry, Stephanie, Schaum, Thomas, Schulz, Christian, Skowasch, Dirk, Taube, Christian, Welte, Tobias, Gleiber, Wolfgang, Brehler, Randolf, Schreiber, Jens, Schuette, Wolfgang, Kronsbein, Juliane, Bonnet, Reiner, Beck, Ekkehard, Lacedonia, Donato, Senna, Gianenrico, Caruso, Cristiano, Crimi, Nunzio, Blasi, Francesco, Santus, Pierachille, Canonica, Giorgio Walter, Guarnieri, Gabriella, Pelaia, Girolamo, Milanese, Manlio, Micheletto, Claudio, Corsico, Angelo Guido, Scichilone, Nicola, Spadaro, Giuseppe, Langeveld, Bas, Holters, Jurgen, Willem van den Berg, Jan, Smit, Arthur, Conemans, Lennart, van Veen, Helena, Staaks, Gerald, Lehmann, Sverre, Echave-Sustaeta, Jose Maria, Ribas, Christian Domingo, de Luiz Martinez, Gustavo, Gonzalez Perez, Ruperto, Garcia Rivero, Juan Luis, Gall, Xavier Muñoz, Soto Campos, Jose Gregorio, Mozo, Paloma Campo, Pan, Carmen Vidal, Fernandez, Ana Gomez-Bastero, Tellez, Sergio Campos, Rivera, Carlos Martinez, Bobolea, Irina Diana, Guerrero, Raquel Morillo, Garcia, Ismael Ali, Rodriguez Hermosa, Juan Luis, Stenfors, Nikolai, Tunsäter, Alf, Curiac, Dan, von Garnier, Christophe, Leuppi, Joerg, Schmid-Grendelmeier, Peter, Nasser, Shuaib, Chaudhuri, Rekha, Nordstrom, Monica, Saralaya, Dinesh, Pfeffer, Paul, Mansur, Adel, Short, Philip, Wenzel, Sally, Cherry, William Brett, Zafra, Heidi, Gonzalez, Erika, Soong, Weily, Davis, Benjamin, Kao, Neil, Hussain, Iftikhar, Maselli Caceres, Diego Jose, Harris, James, Calhoun, William, Rodicio, Ileana, Kaufman, David, Moss, Mark, Sztejman, Eric, DeLeon, Samuel, Sumino, Kaharu, Kashyap, Ravindra, Leflein, Jeffrey, Hajal, Rizan, Fakih, Faisal, Hill, David, Lin, Robert, Jarratt, Mikell, Subramaniam, Vijay, Sussman, Robert, Mumneh, Nayla, Reibman, Joan, Darveaux, Jared, Tan, Ricardo, Tanus, Tonny, Sikand, Vinay, Marshall, Gailen, Mehta, Hemalini, Cole, Jeremy, Goodman, Brad, Goss, Deborah, Bardelas, Jose, Milstone, Aaron, Mehta, Vinay, Clore, Lee, Millard, Mark, Palumbo, Michael, Puppala, Dileep, Leong, Mila, Prenner, Bruce, Robinette, Emory, Heidarian Raissy, Hengameh, Fost, David, Pleskow, Warren, Marcus, Michael, Ilowite, Jonathan, Moore, Wendy, Steven, Gary, De la Cruz, Luis, Chupp, Geoffrey, Berger, William, Randolph, Christopher, Holguin, Fernando, Kureishy, Shahrukh, Campbell, Edward, Peche, Rudi, Pini, Laura, Papi, Alberto, Beghé, Bianca, Peveri, Silvia, Henriquez Santa, Aythamy, Ramos Gonzalez, Jacinto, Vinge, Ines, St. John, Roy, Louis, Renaud, Harrison, Tim W., Chanez, Pascal, Menzella, Francesco, Philteos, George, Cosio, Borja G., Lugogo, Njira L., de Luiz, Gustavo, Burden, Annie, Adlington, Timothy, Keeling, Nanna, Kwiatek, Justin, and Garcia Gil, Esther

Published
2023
Full Text
View/download PDF

9. White paper on peanut allergy – part 1: Epidemiology, burden of disease, health economic aspects

Author

Lange, Lars, Klimek, Ludger, Beyer, Kirsten, Blümchen, Katharina, Novak, Natalija, Hamelmann, Eckard, Bauer, Andrea, Merk, Hans, Rabe, Uta, Jung, Kirsten, Schlenter, Wolfgang, Ring, Johannes, Chaker, Adam, Wehrmann, Wolfgang, Becker, Sven, Mülleneisen, Norbert, Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolf, Fuchs, Thomas, Jakob, Thilo, Ankermann, Tobias, Schmidt, Sebastian M., Gerstlauer, Michael, Zuberbier, Torsten, Spindler, Thomas, and Vogelberg, Christian

Published
2021
Full Text
View/download PDF

10. Immunologically relevant aspects of the new COVID-19 vaccines—an ÖGAI (Austrian Society for Allergology and Immunology) and AeDA (German Society for Applied Allergology) position paper

Author

Untersmayr, Eva, Förster-Waldl, Elisabeth, Bonelli, Michael, Boztug, Kaan, Brunner, Patrick M., Eiwegger, Thomas, Eller, Kathrin, Göschl, Lisa, Grabmeier-Pfistershammer, Katharina, Hötzenecker, Wolfram, Jordakieva, Galateja, Moschen, Alexander R., Pfaller, Birgit, Pickl, Winfried, Reinisch, Walter, Wiedermann, Ursula, Klimek, Ludger, Bergmann, Karl-Christian, Brehler, Randolf, Pfützner, Wolfgang, Novak, Natalija, Merk, Hans, Rabe, Uta, Schlenter, Wolfgang, Ring, Johannes, Wehrmann, Wolfgang, Mülleneisen, Norbert, Wrede, Holger, Fuchs, Thomas, and Jensen-Jarolim, Erika

Published
2021
Full Text
View/download PDF

11. Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI

Author

Klimek, Ludger, Bergmann, Karl-Christian, Brehler, Randolf, Pfützner, Wolfgang, Zuberbier, Torsten, Hartmann, Karin, Jakob, Thilo, Novak, Natalija, Ring, Johannes, Merk, Hans, Hamelmann, Eckard, Ankermann, Tobias, Schmidt, Sebastian, Untersmayr, Eva, Hötzenecker, Wolfram, Jensen-Jarolim, Erika, Brockow, Knut, Mahler, Vera, and Worm, Margitta

Published
2021
Full Text
View/download PDF

12. Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA)

Author

Klimek, Ludger, Novak, Natalija, Hamelmann, Eckard, Werfel, Thomas, Wagenmann, Martin, Taube, Christian, Bauer, Andrea, Merk, Hans, Rabe, Uta, Jung, Kirsten, Schlenter, Wolfgang, Ring, Johannes, Chaker, Adam, Wehrmann, Wolfgang, Becker, Sven, Mülleneisen, Norbert, Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolf, Fuchs, Thomas, Jakob, Thilo, Ankermann, Tobias, Schmidt, Sebastian M., Gerstlauer, Michael, Vogelberg, Christian, Zuberbier, Thomas, Hartmann, Karin, and Worm, Margitta

Published
2021
Full Text
View/download PDF

14. ARIA guideline 2019: treatment of allergic rhinitis in the German health system

Author

Klimek, Ludger, Bachert, Claus, Pfaar, Oliver, Becker, Sven, Bieber, Thomas, Brehler, Randolf, Buhl, Roland, Casper, Ingrid, Chaker, Adam, Czech, Wolfgang, Fischer, Jörg, Fuchs, Thomas, Gerstlauer, Michael, Hörmann, Karl, Jakob, Thilo, Jung, Kirsten, Kopp, Matthias V., Mahler, Vera, Merk, Hans, Mülleneisen, Norbert, Nemat, Katja, Rabe, Uta, Ring, Johannes, Saloga, Joachim, Schlenter, Wolfgang, Schmidt-Weber, Carsten, Seyfarth, Holger, Sperl, Annette, Spindler, Thomas, Staubach, Petra, Strieth, Sebastian, Treudler, Regina, Vogelberg, Christian, Wallrafen, Andrea, Wehrmann, Wolfgang, Wrede, Holger, Zuberbier, Torsten, Bedbrook, Anna, Canonica, Giorgio W., Cardona, Victoria, Casale, Thomas B., Czarlewski, Wienczylawa, Fokkens, Wytske J., Hamelmann, Eckard, Hellings, Peter W., Jutel, Marek, Larenas-Linnemann, Désirée, Mullol, Joaquim, Papadopoulos, Nikolaos G., Toppila-Salmi, Sanna, Werfel, Thomas, and Bousquet, Jean

Published
2019
Full Text
View/download PDF

15. Efficacy and safety of on‐demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial.

Author

Weller, Karsten, Gimenez‐Arnau, Ana Maria, Baron, Jens, Brehler, Randolf, Ferrer, Marta, Groffik, Adriane, Grundmann, Sonja, Jakob, Thilo, Labrador‐Horrillo, Moisés, Müller, Sabine, Staubach, Petra, Wurpts, Gerda, Metz, Martin, and Maurer, Marcus

Subjects
URTICARIA, PREVENTIVE medicine
Abstract

Background: Non‐sedating H1‐antihistamines (nsAH) are the most commonly used treatment for chronic spontaneous urticaria (CSU). Many patients use them as on‐demand (OD) therapy rather than a maintenance treatment. Here, we compared OD versus daily maintenance treatment with the nsAH rupatadine, assessed the efficacy of rupatadine updosing, and investigated potential long‐term disease‐modifying effects. Methods: This multicenter, randomized study consisted of 2 weeks of screening, 8 weeks of double‐blind treatment, and 6 weeks of treatment‐free follow‐up (OD allowed). Adult patients were randomized to 10 mg rupatadine OD or 10 mg rupatadine daily. At Week 4, if patients did not have a complete response, they switched from 10 to 20 mg rupatadine daily or underwent sham updosing (patients on 10 mg rupatadine OD). The primary aim was to compare CSU disease activity at the end of follow‐up between daily versus OD. Additionally, we assessed the efficacy of rupatadine updosing. Major outcomes were disease activity, CSU‐related quality of life (QoL), and disease control. Results: At Week 4, disease activity and QoL significantly improved in daily versus OD‐treated patients. Updosing of rupatadine did not improve the mean disease activity, but the number of complete responders increased during updosing from 5% to 22%. At the end of follow‐up, the disease activity of patients treated OD versus daily was not significantly different. Conclusions: Daily rupatadine treatment significantly improved CSU disease activity and QoL during treatment versus OD treatment but not after discontinuation of rupatadine, indicating the benefits of a daily maintenance nsAH schedule. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Correction to “ARIA guideline 2019: treatment of allergic rhinitis in the German health system”

Author

Klimek, Ludger, Bachert, Claus, Pfaar, Oliver, Becker, Sven, Bieber, Thomas, Brehler, Randolf, Buhl, Roland, Casper, Ingrid, Chaker, Adam, Czech, Wolfgang, Fischer, Jörg, Fuchs, Thomas, Gerstlauer, Michael, Hörmann, Karl, Jakob, Thilo, Jung, Kirsten, Kopp, Matthias V., Mahler, Vera, Merk, Hans, Mülleneisen, Norbert, Nemat, Katja, Rabe, Uta, Ring, Johannes, Saloga, Joachim, Schlenter, Wolfgang, Schmidt-Weber, Carsten, Seyfarth, Holger, Sperl, Annette, Spindler, Thomas, Staubach, Petra, Strieth, Sebastian, Treudler, Regina, Vogelberg, Christian, Wallrafen, Andrea, Wehrmann, Wolfgang, Wrede, Holger, Zuberbier, Torsten, Bedbrook, Anna, Canonica, Giorgio W., Cardona, Victoria, Casale, Thomas B., Czarlewski, Wienczylawa, Fokkens, Wytske J., Hamelmann, Eckard, Hellings, Peter W., Jutel, Marek, Larenas-Linnemann, Désirée, Mullol, Joaquim, Papadopoulos, Nikolaos G., Toppila-Salmi, Sanna, Werfel, Thomas, and Bousquet, Jean

Published
2020
Full Text
View/download PDF

18. Guideline on diagnostic procedures for suspected hypersensitivity to beta-lactam antibiotics: Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) in collaboration with the German Society of Allergology (AeDA), German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Austrian Society for Allergology and Immunology (ÖGAI), and the Paul-Ehrlich Society for Chemotherapy (PEG)

Author

Wurpts, Gerda, Aberer, Werner, Dickel, Heinrich, Brehler, Randolf, Jakob, Thilo, Kreft, Burkhard, Mahler, Vera, Merk, Hans F., Mülleneisen, Norbert, Ott, Hagen, Pfützner, Wolfgang, Röseler, Stefani, Ruëff, Franziska, Sitter, Helmut, Sunderkötter, Cord, Trautmann, Axel, Treudler, Regina, Wedi, Bettina, Worm, Margitta, and Brockow, Knut

Published
2019
Full Text
View/download PDF

22. S2k‐Leitlinie Diagnostik, Prävention und Therapie des Handekzems: S2k guideline diagnosis, prevention and therapy of hand eczema.

Author

Bauer, Andrea, Brans, Richard, Brehler, Randolf, Büttner, Marion, Dickel, Heinrich, Elsner, Peter, Fartasch, Manigé, Herzog, Claudia, John, Swen‐Malte, Köllner, Arno, Maul, Julia‐Tatjana, Merk, Hans, Molin, Sonja, Nast, Alexander, Nikolakis, Georgios D., Schliemann, Sybille, Skudlik, Christoph, Weisshaar, Elke, Werfel, Thomas, and Zidane, Miriam

Abstract

Copyright of Journal der Deutschen Dermatologischen Gesellschaft is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2023
Full Text
View/download PDF

23. S2k guideline diagnosis, prevention, and therapy of hand eczema.

Author

Bauer, Andrea, Brans, Richard, Brehler, Randolf, Büttner, Marion, Dickel, Heinrich, Elsner, Peter, Fartasch, Manigé, Herzog, Claudia, John, Swen‐Malte, Köllner, Arno, Maul, Julia‐Tatjana, Merk, Hans, Molin, Sonja, Nast, Alexander, Nikolakis, Georgios D., Schliemann, Sybille, Skudlik, Christoph, Weisshaar, Elke, Werfel, Thomas, and Zidane, Miriam

Abstract

Summary: The consensus‐based guideline "Diagnosis, prevention, and treatment of hand eczema (HE)" provides concrete instructions and recommendations for diagnosis, prevention, and therapy of HE based on an evidence‐ and consensus‐based approach. The guideline was created based on the German guideline "Management von Handekzemen" from 2009 and the current guideline of the European Society of Contact Dermatitis (ESCD) "Guidelines for diagnosis, prevention, and treatment of hand eczema" from 2022. The general goal of the guideline is to provide dermatologists and allergologists in practice and clinics with an accepted, evidence‐based decision‐making tool for selecting and conducting suitable and sufficient therapy for patients with hand eczema. The guideline is based on two Cochrane reviews of therapeutic and preventive interventions for HE. The remaining chapters were mainly developed and consented based on non‐systematic literature research by the expert group. The expert group consisted of members of allergological and occupational dermatological professional associations and working groups, a patient representative, and methodologists. The proposals for recommendations and key statements were consented by using a nominal group process during a consensus conference on September 15, 2022. The structured consensus‐building process was professionally moderated. This guideline is valid until February 22, 2028. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. Correction to: Guideline for the diagnosis of drug hypersensitivity reactions

Author

Brockow, Knut, Przybilla, Bernhard, Aberer, Werner, Bircher, Andreas J., Brehler, Randolf, Dickel, Heinrich, Fuchs, Thomas, Jakob, Thilo, Lange, Lars, Pfützner, Wolfgang, Mockenhaupt, Maja, Ott, Hagen, Pfaar, Oliver, Ring, Johannes, Sachs, Bernhardt, Sitter, Helmut, Trautmann, Axel, Treudler, Regina, Wedi, Bettina, Worm, Margitta, Wurpts, Gerda, Zuberbier, Torsten, and Merk, Hans F.

Published
2017
Full Text
View/download PDF

27. Immunologisch relevante Aspekte der neuen COVID-19-Impfstoffe

Author

Untersmayr, Eva, Förster-Waldl, Elisabeth, Bonelli, Michael, Boztug, Kaan, Brunner, Patrick M., Eiwegger, Thomas, Eller, Kathrin, Göschl, Lisa, Grabmeier-Pfistershammer, Katharina, Hötzenecker, Wolfram, Jordakieva, Galateja, Moschen, Alexander R., Pfaller, Birgit, Pickl, Winfried, Reinisch, Walter, Wiedermann, Ursula, Klimek, Ludger, Bergmann, Karl-Christian, Brehler, Randolf, Novak, Natalija, Merk, Hans F., Rabe, Uta, Schlenter, Wolfgang W., Ring, Johannes, Wehrmann, Wolfgang, Mülleneisen, Norbert K., Wrede, Holger, Fuchs, Thomas, and Jensen-Jarolim, Erika

Subjects
Immunsuppression, Impfwirkung, COVID-19, Immunantwort, COVID-19-Impfung, Immunmodulation, Leitlinie
Published
2021

29. Praktischer Umgang mit allergischen Reaktionen auf COVID-19-Impfstoffe

Author

Klimek, Ludger, Bergmann, Karl-Christian, Brehler, Randolf, Pfützner, Wolfgang, Worm, Margitta, Hartmann, Karin, Jakob, Thilo, Novak, Natalija, Ring, Johannes, Hamelmann, Eckard, Ankermann, Tobias, Schmidt, Sebastian M., Untersmayr, Eva, Hötzenecker, Wolfram, Jensen-Jarolim, Erika, and Zuberbier, Torsten

Subjects
mRNA-1273, mRNA-Impfstoff, Anaphylaxie, SARS-CoV-2, allergische Reaktion, COVID-19, BNT162b2, Leitlinie
Abstract

Hintergrund: Zur vorbeugenden Behandlung von COVID-19 (Coronaviruserkrankung 2019) wurden in einer beispiellosen weltweiten Forschungsanstrengung Sicherheit und Wirksamkeit neuer Impfstoffplattformen studiert, die noch nie zuvor am Menschen eingesetzt wurden. Weniger als ein Jahr nach der Entdeckung der SARS-CoV-2-Virussequenz (SARS-CoV-2, "severe acute respiratory syndrome coronavirus type 2") wurden diese in zahlreichen Ländern für den Einsatz zugelassen und es wurde mit Massenimpfungen begonnen. Die bislang in der Europäischen Union (EU) zugelassenen mRNA-Impfstoffe (mRNA, "messenger"-RNA) gegen SARS-CoV-2 BNT162b2 und mRNA-1273 basieren auf einer ähnlichen lipidbasierten Nanopartikelträgertechnologie; die Lipidkomponenten unterscheiden sich jedoch. Schwere allergische Reaktionen und Anaphylaxien nach COVID-19-Impfungen sind sehr seltene unerwünschte Nebenwirkungen, die aber aufgrund potenziell letaler Ausgänge viel Aufmerksamkeit erhalten und ein hohes Maß an Verunsicherung ausgelöst haben. Methoden: Das aktuelle Wissen zu anaphylaktischen Reaktionen auf Impfstoffe und speziell zu den derzeit neuen mRNA-COVID-19-Impfstoffen wurde zusammengestellt mittels einer Literaturanalyse durch Recherchen in Medline, Pubmed sowie den nationalen und internationalen Studien- und Leitlinienregistern, der Cochrane Library und dem Internet unter besonderer Berücksichtigung offizieller Webseiten der World Health Oranization (WHO), der Centers for Disease Control and Prevention (CDC), der European Medicines Agency (EMA), des Robert-Koch-Instituts (RKI) und des Paul-Ehrlich-Instituts (PEI). Ergebnisse: Basierend auf der internationalen Literatur und bisheriger Erfahrungen zu schweren allergischen Reaktionen im Kontext der COVID-19-Impfungen werden von einem Expertengremium Empfehlungen für Prophylaxe, Diagnostik und Therapie dieser allergischen Reaktionen gegeben. Schlussfolgerung: Vor einer COVID-19-Impfung mit den derzeit zugelassenen Impfstoffen sind Allergietests für die allermeisten Allergiker nicht notwendig. Bei allergischer/anaphylaktischer Reaktion auf den verabreichten COVID-19-Impfstoff wird eine allergologische Abklärung empfohlen, wie auch für eine kleine potenzielle Risikopopulation vor der ersten Impfung. Die Evaluierung und Zulassung von Testverfahren sollten hierfür erfolgen. Zitierweise: Klimek L, Bergmann K-C, Brehler R, Pfützner W, Zuberbier T, Hartmann K, Jakob T, Novak N, Ring J, Merk H; Hamelmann E, Ankermann T, Schmidt S, Untersmayr E, Hötzenecker W, Jensen-Jarolim E, Brockow K, Mahler V, Worm M. Practical Handling of Allergic Reactions to COVID-19 vaccines. A Position Paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI. Allergo J Int 2021;30:79-95 https: //doi.org/10.1007/s40629-021-00165-7

Published
2021

31. Schwere allergische Reaktionen nach COVID-19-Impfung mit dem Impfstoff von Pfizer/BioNTech in Großbritannien und USA

Author

Klimek, Ludger, Novak, Natalija, Hamelmann, Eckard, Werfel, Thomas, Wagenmann, Martin, Taube, Christian, Bauer, Andrea, Merk, Hans F., Rabe, Uta, Jung, Kirsten, Schlenter, Wolfgang W., Ring, Johannes, Chaker, Adam M., Wehrmann, Wolfgang, Becker, Sven, Mülleneisen, Norbert K., Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolf, Fuchs, Thomas, Jakob, Thilo, Ankermann, Tobias, Schmidt, Sebastian M., Gerstlauer, Michael, Vogelberg, Christian, Zuberbier, Torsten, Hartmann, Karin, and Worm, Margitta

Subjects
Anaphylaxie, mRNA, Umschlag, BNT162b2, schwere allergische Reaktion, Impfstoffe
Abstract

Zwei Mitarbeiter des National Health Service (NHS) in England entwickelten nach der Verabreichung des BNT162b2-Impfstoffs von BionNTech gegen COVID-19 schwere allergische Reaktionen. Die britische Fachinformation für den BNT162b2-Impfstoff enthält bereits Hinweise auf eine Kontraindikation zur Anwendung bei Personen, die allergisch auf den Impfstoff oder einen seiner Bestandteile reagiert haben. Als Vorsichtsmaßnahme hat die englische Regulationsbehörde für Arzneimittel und Gesundheitsprodukte (MHRA) eine vorläufige Anleitung herausgegeben, "Patienten mit schweren Allergien" grundsätzlich nicht zu impfen. Allergische Reaktionen auf Impfstoffe sind sehr selten, aber Impfstoffkomponenten verursachen bekanntermaßen allergische Reaktionen. BNT162b2 ist ein Impfstoff, der auf einer in Lipidnanopartikel eingebetteten mRNA basiert und mit weiteren Substanzen angereichert wird, um den Transport in die Zellen zu ermöglichen. In der zentralen klinischen Phase-III-Studie wurde der BNT162b2-Impfstoff im Allgemeinen gut vertragen. Impfstoffe gelten als eine der wirksamsten Maßnahmen im Bereich der öffentlichen Gesundheit. Schwere allergische Reaktionen auf Impfstoffe sind selten, können jedoch lebensbedrohlich sein. Es ist ratsam, die Impfteams auf diese Gefahr aufmerksam zu machen und angemessene Vorsichtsmaßnahmen zu treffen, während mehr Erfahrungen mit dem neuen Impfstoff gesammelt werden.

Published
2021

32. S3 Guideline Urticaria. Part 2: Treatment of urticaria – German‐language adaptation of the international S3 guideline.

Author

Zuberbier, Torsten, Altrichter, Sabine, Bauer, Sabine, Brehler, Randolf, Brockow, Knut, Dressler, Corinna, Fluhr, Joachim, Gaskins, Matthew, Hamelmann, Eckard, Kühne, Kathrin, Merk, Hans, Mülleneisen, Norbert K., Nast, Alexander, Olze, Heidi, Ott, Hagen, Pleimes, Marc, Ruëff, Franziska, Staubach‐Renz, Petra, Wedi, Bettina, and Maurer, Marcus

Abstract

Summary: This publication is the second part of the German‐language S3 guideline on urticaria. It covers the management of urticaria and should be used together with Part 1 of the guideline on classification and diagnosis. This publication was prepared according to the criteria of the AWMF on the basis of the international English‐language S3 guideline with special consideration of health system conditions in German‐speaking countries. Chronic urticaria has a high impact on the quality of life and daily activities of patients. Therefore, if causal factors cannot be eliminated, effective symptomatic treatment is necessary. The recommended first‐line treatment is to administer new generation, non‐sedating H1 antihistamines. If the standard dose is not sufficiently effective, the dose should be increased up to fourfold. For patients who do not respond to this treatment, the second‐line treatment in addition to antihistamines in the treatment algorithm is omalizumab and, if this treatment fails, ciclosporin. Other low‐evidence therapeutic agents should only be used if all treatments in the treatment algorithm agreed upon by the guideline group fail. Both the benefit‐risk profile and cost should be considered. Corticosteroids are not recommended for long‐term treatment due to their inevitable severe side effects. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. S3‐Leitlinie Urtikaria. Teil 2: Therapie der Urtikaria – deutschsprachige Adaption der internationalen S3‐Leitlinie.

Author

Zuberbier, Torsten, Altrichter, Sabine, Bauer, Sabine, Brehler, Randolf, Brockow, Knut, Dressler, Corinna, Fluhr, Joachim, Gaskins, Matthew, Hamelmann, Eckard, Kühne, Kathrin, Merk, Hans, Mülleneisen, Norbert K., Nast, Alexander, Olze, Heidi, Ott, Hagen, Pleimes, Marc, Ruëff, Franziska, Staubach‐Renz, Petra, Wedi, Bettina, and Maurer, Marcus

Abstract

Copyright of Journal der Deutschen Dermatologischen Gesellschaft is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2023
Full Text
View/download PDF

34. S3‐Leitlinie Urtikaria. Teil 1: Klassifikation und Diagnostik der Urtikaria – deutschsprachige Adaptation der internationalen S3‐Leitlinie.

Author

Zuberbier, Torsten, Altrichter, Sabine, Bauer, Sabine, Brehler, Randolf, Brockow, Knut, Dressler, Corinna, Fluhr, Joachim, Gaskins, Matthew, Hamelmann, Eckard, Kühne, Kathrin, Merk, Hans, Mülleneisen, Norbert K., Nast, Alexander, Olze, Heidi, Ott, Hagen, Pleimes, Marc, Ruëff, Franziska, Staubach‐Renz, Petra, Wedi, Bettina, and Maurer, Marcus

Abstract

Copyright of Journal der Deutschen Dermatologischen Gesellschaft is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2023
Full Text
View/download PDF

35. S3 Guideline Urticaria. Part 1: Classification and diagnosis of urticaria – German‐language adaptation of the international S3 Guideline.

Author

Zuberbier, Torsten, Altrichter, Sabine, Bauer, Sabine, Brehler, Randolf, Brockow, Knut, Dressler, Corinna, Fluhr, Joachim, Gaskins, Matthew, Hamelmann, Eckard, Kühne, Kathrin, Merk, Hans, Mülleneisen, Norbert K., Nast, Alexander, Olze, Heidi, Ott, Hagen, Pleimes, Marc, Ruëff, Franziska, Staubach‐Renz, Petra, Wedi, Bettina, and Maurer, Marcus

Abstract

Summary: The lifetime prevalence of urticaria, a severe allergic disease, is almost 20%. It not only limits the quality of life of those affected, but also their general performance at work and in their daily activities. This publication is the first section of the Urticaria Guideline. It covers the classification and diagnosis of urticaria, taking into account the major advances in research into its causes, triggering factors and pathomechanisms. It also addresses strategies for the efficient diagnosis of the different subtypes of urticaria. This is crucial for individual, patient‐oriented treatment, which is covered in the second part of the guideline, published separately. This German‐language guideline was developed according to the criteria of the AWMF on the basis of the international English‐language S3 guideline with special consideration of health system characteristics in the German‐speaking countries. This first part of the guideline describes the classification of urticaria, distinguishing spontaneously occurring wheals (hives) and angioedema from forms of urticaria with inducible symptoms. Urticaria is defined as sudden onset of wheals, angioedema, or both, but is to be distinguished from conditions in which wheals occur as a short‐term symptom, such as anaphylaxis. The diagnosis is based on (a limited number of) laboratory tests, but especially on medical history. In addition, validated instruments are available to measure the severity, activity and course of the disease. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

36. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM)

Author

Brockow, Knut, Przybilla, Bernhard, Aberer, Werner, Bircher, Andreas J., Brehler, Randolf, Dickel, Heinrich, Fuchs, Thomas, Jakob, Thilo, Lange, Lars, Pfützner, Wolfgang, Mockenhaupt, Maja, Ott, Hagen, Pfaar, Oliver, Ring, Johannes, Sachs, Bernhardt, Sitter, Helmut, Trautmann, Axel, Treudler, Regina, Wedi, Bettina, Worm, Margitta, Wurpts, Gerda, Zuberbier, Torsten, and Merk, Hans F.

Published
2015
Full Text
View/download PDF

37. Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen Covid-19-Pandemiea, b, c

Author

Klimek, Ludger, Pfaar, Oliver, Worm, Margitta, Eiwegger, Thomas, Hagemann, Jan, Ollert, Markus, Untersmayr, Eva, Hoffmann-Sommergruber, Karin, Vultaggio, Alessandra, Agache, Ioana, Bavbek, Sevim, Bossios, Apostolos, Casper, Ingrid, Chan, Susan, Chatzipetrou, Alexia, Vogelberg, Christian, Firinu, Davide, Kauppi, Paula, Kolios, Antonios, Kothari, Akash, Matucci, Andrea, Palomares, Oscar, Szépfalusi, Zsolt, Pohl, Wolfgang, Hötzenecker, Wolfram, Rosenkranz, Alexander, Bergmann, Karl-Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen, Darsow, Ulf, Keil, Thomas, Kleine-Tebbe, Jörg, Lau, Susanne, Maurer, Marcus, Merk, Hans, Mösges, Ralph, Saloga, Joachim, Staubach, Petra, Jappe, Uta, Rabe, Claus, Rabe, Uta, Vogelmeier, Claus, Biedermann, Tilo, Jung, Kirsten, Schlenter, Wolfgang, Ring, Johannes, Chaker, Adam, Wehrmann, Wolfgang, Becker, Sven, Freudelsperger, Laura, Mülleneisen, Norbert, Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolf, Fuchs, Thomas, Tomazic, Peter-Valentin, Aberer, Werner, Fink Wagner, Antje, Horak, Fritz, Wöhrl, Stefan, Niederberger-Leppin, Verena, Pali-Schöll, Isabella, Roller-Wirnsberger, Regina, Spranger, Otto, Valenta, Rudolf, Akdis, Mübecell, Matricardi, Paolo M., Spertini, François, Khaltaev, Nikolai, Michel, Jean-Pierre, Nicod, Larent, Schmid-Grendelmeier, Peter, Idzko, Marco, Hamelmann, Eckard, Jakob, Thilo, Werfel, Thomas, Wagenmann, Martin, Taube, Christian, Jensen-Jarolim, Erika, Korn, Stephanie, Hentges, Francois, Schwarze, Jürgen, O´Mahony, Liam, Knol, Edward, del Giacco, Stefano, Chivato, Tomás, Bousquet, Jean, Zuberbier, Torsten, Akdis, Cezmi, and Jutel, Marek

Subjects
Titel, SARS-CoV-2, Medizin, Immunology and Allergy, Omalizumab, Benralizumab, Dupilumab, Reslizumab, Covid-19, Telemedizin, Mepolizumab
Published
2020

38. Management of suspected and confirmed COVID‐19 (SARS‐CoV‐2) vaccine hypersensitivity.

Author

Worm, Margitta, Alexiou, Aikaterina, Bauer, Andrea, Treudler, Regina, Wurpts, Gerda, Dickel, Heinrich, Buhl, Timo, Müller, Sabine, Jung, Andreas, Brehler, Randolf, Fluhr, Joachim, Klimek, Ludger, Mülleneisen, Norbert, Pfützner, Wolfgang, Raap, Ulrike, Roeseler, Stefani, Schuh, Sandra, Timmermann, Hartmut, Heine, Guido, and Wedi, Bettina

Subjects
URTICARIA, COVID-19 vaccines, ALLERGIES, SARS-CoV-2, COVID-19, VACCINES
Abstract

Background: Systemic allergic reactions to vaccines are very rare. In this study we assessed the management and outcome of suspected SARS‐CoV‐2 vaccine hypersensitivity. Methods: Totally, 334 individuals underwent an allergy work up regarding SARS‐CoV‐2 vaccination (group A: 115 individuals suspected to be at increased risk for vaccine‐related reactions before vaccination and group B: 219 patients with reactions after COVID vaccination). The large majority of the SPT/IDT with the vaccines were negative; however, we identified in 14.1% (n = 47) a possible sensitization to the SARS‐CoV‐2 vaccine and/or its ingredients defined as one positive skin test. Of the 219 individuals (group B) who experienced symptoms suspicious for a hypersensitivity reaction after vaccination, 214 were reported after the first vaccination with a mRNA vaccine (157 mRNA (Comirnaty®, 38 Spikevax®) and 18 with a vector vaccine (Vaxzevria®), 5 cases were after the second vaccination. Results: The symptom profile in group B was as follows: skin symptoms occurred in 115 cases (n = 59 angioedema, n = 50 generalized urticaria and n = 23 erythema/flush. Seventy individuals had cardiovascular, 53 respiratory and 17 gastrointestinal symptoms. Of the overall 334 individuals, 78 patients tolerated (re)‐vaccination (out of skin test positive/negative 7/19 from group A and 17/35 from group B). Conclusion: Proven IgE‐mediated hypersensitivity to SARS‐CoV‐2 vaccines is extremely rare and not increased in comparison with reported hypersensitivity to other vaccines. The value of skin tests is unclear and nonspecific reactions, in particular when intradermal testing is applied, should be considered. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

39. The European Curriculum for Additional Qualification Allergology A Position Paper by Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA) in cooperation with European Academy for Allergology and Clinical Immunology (EAACI) and Allergology Section of European Union of Medical Specialists (UEMS)

Author

Muelleneisen, Norbert, Klimek, Ludger, Worm, Margitta, Merk, Hans, Rabe, Uta, Biedermann, Tilo, Jung, Kirsten, Schlenter, Wolfgang, Ring, Johannes, Chaker, Adam, Wehrmann, Wolfgang, Becker, Sven, Bergmann, Karl-Christian A., Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolf, Fuchs, Thomas, Matricardi, Paolo, Hamelmann, Eckard, Jakob, Thilo, Werfel, Thomas, Wagenmann, Martin, Taube, Christian, Gerstlauer, Michael, Vogelberg, Christian, Van Wijk, Roy Gerth, Eguiluz-Gracia, Ibon, Gayraud, Jacques, Gutermuth, Jan, Heffler, Enrico, Popov, Todor A., Schmid-Grendelmeier, Peter, Tomazic, Peter, V, Tsilochristou, Olympia, Del Giacco, Stefano, Zuberbier, Torsten, Jutel, Marek, Artificial Intelligence supported Modelling in clinical Sciences, Gerontology, Skin function and permeability, and Dermatology

Subjects
The European Curriculum for Additional Qualification Allergolog, Dermatology
Published
2021

42. Contact sensitization to essential oils: IVDK data of the years 2010–2019.

Author

Geier, Johannes, Schubert, Steffen, Reich, Kristian, Skudlik, Christoph, Ballmer‐Weber, Barbara, Brehler, Randolf, Weisshaar, Elke, and Uter, Wolfgang

Subjects
ESSENTIAL oils, ALLERGENS, AROMATHERAPY, NATUROPATHY, INFORMATION networks
Abstract

Background: Essential oils (EOs) are widely used in cosmetics, perfumes, massage fluids, aroma therapy and natural medicine. Some EOs contain contact sensitizers. Objectives: To describe the frequency of sensitization to EOs in dermatitis patients presenting in skin clinics including concomitant reactions, to evaluate the EO patch test preparations and to identify patient groups with an increased risk of EO sensitization. Patients and methods: Retrospective analysis of data from the Information Network of Departments of Dermatology (IVDK), 2010–2019. Results: Twelve EOs were patch tested in an aimed manner in 10 930 patients, of whom 908 (8.3%) reacted to at least 1 EO. Only 6 EOs elicited more than 1% positive patch test reactions: ylang ylang (I + II) oil (3.9%), lemongrass oil (2.6%), jasmine absolute (1.8%), sandalwood oil (1.8%), clove oil (1.6%) and neroli oil (1.1%). Concomitant reactions among EOs or to EOs and fragrances were frequent. Among EO‐positive patients, women, leg dermatitis patients, patients aged 40 years or more, masseurs and cosmeticians were over‐represented. Conclusions: Sensitization to EOs occurs, albeit infrequently in most cases. Masseurs and cosmeticians have an increased risk of sensitization to EOs. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

44. German S1 guideline: Contact dermatitis.

Author

Dickel, Heinrich, Bauer, Andrea, Brehler, Randolf, Mahler, Vera, Merk, Hans F., Neustädter, Irena, Strömer, Klaus, Werfel, Thomas, Worm, Margitta, and Geier, Johannes

Abstract

Summary: Contact dermatitis is an inflammation of the epidermis and dermis at the site of exposure triggered by external agents. The two main forms are irritant and allergic contact dermatitis, which cause significant health and socioeconomic costs in addition to a marked reduction in quality of life. The anamnesis and the clinical picture are decisive for the necessary diagnostic measures. The most accurate possible diagnostic classification of contact dermatitis by means of allergological testing is important for disease management, since not only classical eczema therapy but also avoidance of the exogenous triggering factors are of great importance here. The choice of therapy should be based on the acuity, clinical severity, morphology of the lesions and localization of the contact dermatitis. A combination of basic therapy, topical, physical, and systemic therapy adapted to the patient's needs is required, whereby not all forms of therapy must be carried out simultaneously but can be used in a varying manner. Primary, secondary, and tertiary prevention strategies aim at the recognition of the triggering noxae or allergens with subsequent contact avoidance or minimization. The present S1‐guideline on contact dermatitis is primarily intended to provide dermatologists, allergologists and physicians working in allergology and occupational dermatology with a decision‐making aid for the selection and implementation of suitable and sufficient diagnostics, therapy, and prevention. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

45. S1‐Leitlinie Kontaktekzem.

Author

Dickel, Heinrich, Bauer, Andrea, Brehler, Randolf, Mahler, Vera, Merk, Hans F., Neustädter, Irena, Strömer, Klaus, Werfel, Thomas, Worm, Margitta, and Geier, Johannes

Abstract

Copyright of Journal der Deutschen Dermatologischen Gesellschaft is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2022
Full Text
View/download PDF

46. Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic:Position paper of Ärzteverband Deutscher Allergologen (AeDA)A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)B, Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)C, Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI)D, Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI)E, Österreichische Gesellschaft für Pneumologie (ÖGP)F in co-operation with the German, Austrian, and Swiss ARIA groupsG, and the European Academy of Allergy and Clinical Immunology (EAACI)

Author

Klimek, Ludger, Pfaar, Oliver, Worm, Margitta, Eiwegger, Thomas, Hagemann, Jan, Ollert, Markus, Untersmayr, Eva, Hoffmann-Sommergruber, Karin, Vultaggio, Alessandra, Agache, Ioana, Bavbek, Sevim, Bossios, Apostolos, Casper, Ingrid, Chan, Susan, Chatzipetrou, Alexia, Vogelberg, Christian, Firinu, Davide, Kauppi, Paula, Kolios, Antonios, Kothari, Akash, Matucci, Andrea, Palomares, Oscar, Szépfalusi, Zsolt, Pohl, Wolfgang, Hötzenecker, Wolfram, Rosenkranz, Alexander, Bergmann, Karl-Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen, Darsow, Ulf, Keil, Thomas, Kleine-Tebbe, Jörg, Lau, Susanne, Maurer, Marcus, Merk, Hans, Mösges, Ralph, Saloga, Joachim, Staubach, Petra, Jappe, Uta, Rabe, Klaus, Rabe, Uta, Vogelmeier, Claus, Biedermann, Tilo, Jung, Kirsten, Schlenter, Wolfgang, Ring, Johannes, Chaker, Adam, Wehrmann, Wolfgang, Becker, Sven, Freudelsperger, Laura, Mülleneisen, Norbert, Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolf, Fuchs, Thomas, Tomazic, Peter-Valentin, Aberer, Werner, Fink-Wagner, Antje-Henriette, Horak, Fritz, Wöhrl, Stefan, Niederberger-Leppin, Verena, Pali-Schöll, Isabella, Roller-Wirnsberger, Regina, Spranger, Otto, Valenta, Rudolf, Akdis, Mübecell, Matricardi, Paolo, Spertini, François, Khaltaev, Nicolai, Michel, Jean-Pierre, Nicod, Larent, Schmid-Grendelmeier, Peter, Idzko, Marco, Hamelmann, Eckard, Jakob, Thilo, Werfel, Thomas, Wagenmann, Martin, Taube, Christian, Jensen-Jarolim, Erika, Korn, Stephanie, Hentges, Francois, Schwarze, Jürgen, O Mahony, Liam, Knol, Edward, Del Giacco, Stefano, Chivato Pérez, Tomás, Bousquet, Jean, Bedbrook, Anna, Zuberbier, Torsten, Akdis, Cezmi, Jutel, Marek, Zentrum für Rhinologie und Allergologie [Wiesbaden, Germany], Philipps Universität Marburg, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], The Hospital for sick children [Toronto] (SickKids), University of Toronto, Johannes Gutenberg - Universität Mainz (JGU), Luxembourg Institute of Health (LIH), University of Southern Denmark (SDU), Medizinische Universität Wien = Medical University of Vienna, Careggi University Hospital [Florence, Italie], Transylvania University, Ankara University School of Medicine [Turkey], Karolinska University Hospital [Stockholm], Karolinska Institutet [Stockholm], University hospital of Zurich [Zurich], Universität Zürich [Zürich] = University of Zurich (UZH), Guy's and St Thomas' Hospital [London], King‘s College London, National Technical University of Athens [Athens] (NTUA), University General Hospital ' Attikon ' [Athens, Greece], University of Athens Medical School [Athens], Universitätsklinikum Carl Gustav Carus Dresden, University of Cagliari, Harvard Medical School [Boston] (HMS), Österreichische Forschungsförderungsgesellschaft, Universidad Complutense de Madrid = Complutense University of Madrid [Madrid] (UCM), Kepler University Hospital, Medizinische Universität Graz, Universitätsklinikum Bonn (UKB), Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Helmholtz-Zentrum München (HZM), Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), University of Würzburg = Universität Würzburg, Allergie- & Asthma-Zentrum Berlin Westend, Universitätsklinikum RWTH Aachen - University Hospital Aachen [Aachen, Germany] (UKA), RWTH Aachen University, Universität zu Köln, Clinical Research International Ltd [Hamburg, Germany] (CRI), University Medical Center [Mainz], Universität zu Lübeck [Lübeck], German Research Center for Environmental Health - Helmholtz Center München (GmbH), Universitätsklinikum Tübingen - University Hospital of Tübingen, Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen, Asthma und Allergiezentrum [Leverkusen], Universitätsklinikum Münster [Munster, Germany], University of Göttingen - Georg-August-Universität Göttingen, Universität Wien, Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), University of Geneva [Switzerland], Universitätsspital Zürich (USZ), Universität Bielefeld = Bielefeld University, Justus-Liebig-Universität Gießen (JLU), Medizinische Hochschule Hannover (MHH), Universitatsklinikum Dusseldorf, Dusseldorf Germany, Universitätsklinikum Essen [Universität Duisburg-Essen] (Uniklinik Essen), Centre Hospitalier de Luxembourg [Luxembourg] (CHL), University of Edinburgh, APC Microbiome Ireland, University College Cork (UCC), University Medical Center [Utrecht], Universita degli Studi di Cagliari [Cagliari], University of San Pablo, Humboldt-Universität zu Berlin, Wroclaw Medical University [Wrocław, Pologne], and Technische Universität München [München] (TUM)

Subjects
benralizumab, SARS-CoV-2, COVID-19, mepolizumab, Benralizumab, Omalizumab, Dupilumab, reslizumab, Telemedicine, dupilumab, omalizumab, telemedicine, Reslizumab, Covid-19, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Mepolizumab
Abstract

International audience; Background: Since the beginning of the COVID-19 pandemic, the treatment of patients with allergic and atopy-associated diseases has faced major challenges. Recommendations for "social distancing" and the fear of patients becoming infected during a visit to a medical facility have led to a drastic decrease in personal doctor-patient contacts. This affects both acute care and treatment of the chronically ill. The immune response after SARS-CoV-2 infection is so far only insufficiently understood and could be altered in a favorable or unfavorable way by therapy with monoclonal antibodies. There is currently no evidence for an increased risk of a severe COVID-19 course in allergic patients. Many patients are under ongoing therapy with biologicals that inhibit type 2 immune responses via various mechanisms. There is uncertainty about possible immunological interactions and potential risks of these biologicals in the case of an infection with SARS-CoV-2.Materials and methods: A selective literature search was carried out in PubMed, Livivo, and the internet to cover the past 10 years (May 2010 - April 2020). Additionally, the current German-language publications were analyzed. Based on these data, the present position paper provides recommendations for the biological treatment of patients with allergic and atopy-associated diseases during the COVID-19 pandemic.Results: In order to maintain in-office consultation services, a safe treatment environment must be created that is adapted to the pandemic situation. To date, there is a lack of reliable study data on the care for patients with complex respiratory, atopic, and allergic diseases in times of an imminent infection risk from SARS-CoV-2. Type-2-dominant immune reactions, as they are frequently seen in allergic patients, could influence various phases of COVID-19, e.g., by slowing down the immune reactions. Theoretically, this could have an unfavorable effect in the early phase of a SARS-Cov-2 infection, but also a positive effect during a cytokine storm in the later phase of severe courses. However, since there is currently no evidence for this, all data from patients treated with a biological directed against type 2 immune reactions who develop COVID-19 should be collected in registries, and their disease courses documented in order to be able to provide experience-based instructions in the future.Conclusion: The use of biologicals for the treatment of bronchial asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, and spontaneous urticaria should be continued as usual in patients without suspected infection or proven SARS-CoV-2 infection. If available, it is recommended to prefer a formulation for self-application and to offer telemedical monitoring. Treatment should aim at the best possible control of difficult-to-control allergic and atopic diseases using adequate rescue and add-on therapy and should avoid the need for systemic glucocorticosteroids. If SARS-CoV-2 infection is proven or reasonably suspected, the therapy should be determined by weighing the benefits and risks individually for the patient in question, and the patient should be involved in the decision-making. It should be kept in mind that the potential effects of biologicals on the immune response in COVID-19 are currently not known. Telemedical offers are particularly desirable for the acute consultation needs of suitable patients.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results